Retatrutide vs Survodutide: Triple-Agonist vs Dual-Agonist Compared

Retatrutide and survodutide are the two next-generation metabolic peptides most often confused, because both do the thing the first generation did not: recruit the glucagon receptor for weight loss. But they arrive at that from opposite directions. Retatrutide is the maximalist: it keeps both incretin receptors (GLP-1 and GIP) and adds glucagon, making it the first triple agonist. Survodutide is the minimalist of the glucagon compounds: it drops GIP entirely and runs GLP-1 with glucagon alone. ^[3]

This is an evidence-first comparison: the trial figures, the mechanism, the tolerability and dosing differences, where each sits in development, and who each compound is actually right for. Everything here reports what the published clinical literature describes; none of it is medical advice, and neither compound is approved for human use. We sell retatrutide as a research compound; survodutide is discussed here purely for comparison.

Retatrutide vs survodutide at a glance

The single-line version: retatrutide has the higher weight-loss number and the more complete receptor coverage; survodutide has a leaner mechanism and a purpose-built liver-disease dataset. The rest of this article is what sits behind each of those columns.

Which produces more weight loss: the head-to-head numbers

The headline comparison is the one everyone searches for, so start there. The standing caveat is that these figures come from separate trials, not one study that randomized people to both compounds. No head-to-head retatrutide-versus-survodutide trial has reported results.

Two things stand out. First, retatrutide's top-dose mean (24.2%) exceeds survodutide's top-dose mean (about 18.7%) at a nearly matched duration, 48 weeks against 46. ^{[1] [2]} Second, retatrutide's response curve had not clearly plateaued by week 48, so the measured gap may understate the true difference at a like-for-like endpoint. The honest framing is that this is a strong cross-trial signal, not causal proof: different sites, different populations, different titration schedules.

What actually separates them: triple vs dual agonist mechanism

The efficacy gap traces to a mechanistic difference you can state in one sentence: retatrutide activates three receptors, survodutide activates two, and the missing one is GIP.

Both compounds share two of the three levers: the GLP-1 arm that drives appetite suppression and glucose handling, and the glucagon arm that adds energy expenditure and acts on liver fat. What retatrutide has and survodutide does not is GIP. GIP appears to amplify GLP-1's effects rather than act alone, which is widely understood to be why adding it improved on single-receptor GLP-1 drugs in the first place. ^[3] Retatrutide keeps that amplifier; survodutide runs without it.

That makes survodutide a genuinely different kind of dual agonist from the one most readers know. Tirzepatide is also a dual agonist, but it pairs GLP-1 with GIP (the two incretin receptors) and leaves glucagon out. Survodutide pairs GLP-1 with glucagon and leaves GIP out. So the two most prominent dual agonists in the field share only the GLP-1 backbone; their second receptor is different. Retatrutide is the only one of the three that carries all of it. If tirzepatide is in your comparison set too, the retatrutide vs tirzepatide breakdown covers that dual-vs-triple contrast directly.

The glucagon receptor is the part both retatrutide and survodutide are betting on. On its own, glucagon raises blood glucose, which is why it seems counterintuitive in a metabolic drug. But paired with GLP-1 coverage, its useful contribution (increased energy expenditure and lipid mobilization) is retained while the incretin arm offsets the glycemic penalty. ^[3] That shared bet is why both compounds report liver-fat benefits; the difference is that retatrutide backs it with a second incretin receptor and survodutide keeps the mechanism lean. The full breakdown of the triple mechanism is in how retatrutide works.

Side effects and tolerability: how the profiles compare

Both compounds share the same dominant side-effect story, because both are built on the same GLP-1 foundation.

The gastrointestinal effects are the shared headline: nausea, vomiting, diarrhea, constipation, and reduced appetite, all dose-dependent and concentrated during dose escalation, then easing at a stable dose. ^{[1] [2]} This is the class signature, and it is why both compounds are titrated gradually rather than started at target. In survodutide's Phase 2 program, the rate at which the dose was escalated was itself a variable: slower titration was associated with better tolerability, which is a clean illustration of why the ramp exists. ^[2]

Both compounds also carry the glucagon arm, and one thing to watch with any glucagon agonist is a modest increase in heart rate, reported across these trials. ^[2] The one profile difference worth naming on the retatrutide side is a dose-dependent skin-sensation effect (dysesthesia, tingling or altered sensation) at higher doses, reported in its Phase 2 data and not a characteristic survodutide finding. ^[1] As always, the specifics of incidence and severity are trial-reported and should be read as study findings, not as an individual prediction. Retatrutide's side effects are covered in depth in the retatrutide side effects guide.

Why both cause GI effects, and why they fade

The gastrointestinal effects are not incidental; they are a direct extension of the shared GLP-1 mechanism. GLP-1 receptor activation slows gastric emptying, which is part of how both compounds reduce appetite, and the same slowing is what produces nausea when it happens too abruptly. That is why the effects are worst during dose escalation, when exposure is changing fastest, and why they settle once the dose stabilizes. In both trial designs, the stepwise titration exists precisely to give the system time to adapt at each level. ^[2] None of this is dosing advice: it is the trial-reported rationale for why both escalation schedules look the way they do.

Dosing and titration: how the cadence compares

On the surface these two are near-identical to run: both are once-weekly subcutaneous compounds with multi-week stepwise titration. The differences are in the numbers, and the numbers do not translate across compounds.

The most important thing to understand about the dose columns is that the milligram numbers are not comparable between compounds. Retatrutide's 12 mg and survodutide's 4.8 mg are not measuring the same thing: potency per milligram differs, so a smaller number does not mean a weaker compound or a bigger number a stronger one. What matters is the mean effect at each compound's own top studied dose, which is the column in the weight-loss table above.

Both cadences work because both molecules are engineered for extended action that supports weekly dosing. Retatrutide's roughly 6-day half-life is well characterized; ^[5] the practical consequence is shared: plasma levels build over weeks and reach steady state in about ~4–5 weeks, so early readings systematically understate either compound. The retatrutide pharmacokinetics are detailed in the half-life guide. The most common mistake with either compound is reading the quiet first month as failure; the levels are still climbing, which is exactly why trial endpoints are reported at 46 and 48 weeks rather than early. ^{[1] [2]}

Beyond the scale: liver fat and metabolic breadth

Because both compounds recruit glucagon, both act on the liver, but survodutide is the one that turned that into a dedicated program.

Survodutide was studied directly in MASH (metabolic dysfunction-associated steatohepatitis, the serious form of fatty liver disease), and its Phase 2 MASH trial reported high rates of histological improvement in liver disease without worsening of fibrosis compared with placebo. ^[4] That is a meaningful distinction: rather than inferring a liver benefit from an imaging endpoint, survodutide's program measured it on biopsy in a disease population. This is where the dual GLP-1/glucagon design has arguably its clearest dedicated evidence.

Retatrutide reported its liver effect as a secondary endpoint in the obesity Phase 2: large reductions in liver fat measured by MRI-PDFF, alongside improvements in triglycerides and blood pressure. ^[1] Mechanistically this is coherent: the glucagon arm's effect on hepatic energy turnover and lipid handling is exactly where you would expect liver-fat changes to show up. So the fair reading is that both compounds move liver fat via the same glucagon lever, but survodutide currently has the more targeted liver-disease dataset, while retatrutide has the larger overall weight-loss signal.

Development stage: where each sits

Neither compound is approved, but both cleared Phase 2 and moved into confirmatory Phase 3.

Phase 2 establishes promise; Phase 3 is where a compound has to hold up in larger, longer, more rigorous testing. Both are in that stage now, which means the definitive human safety and efficacy figures for either compound are still being generated. For a research program, that is precisely the point: these are frontier compounds, and the confirmatory data are the story to come.

Who each compound is right for

Neither compound is universally "better"; they sit at different points on an efficacy-versus-mechanism map.

Put plainly: retatrutide is the maximal-effect frontier, and survodutide is the focused dual agonist with the standout liver-disease dataset. If the research question is about the largest achievable mean weight loss and the most complete incretin-plus-glucagon coverage, retatrutide is the compound. If the question is specifically about the GLP-1/glucagon combination, or about liver disease measured directly, survodutide is the more targeted tool. Both are investigational, so neither carries the long-term human data that only time and Phase 3 completion produce.

If semaglutide, tirzepatide, or the branded GLP-1 drugs are also in your comparison set, the retatrutide vs tirzepatide and retatrutide vs Ozempic/Wegovy breakdowns extend this same framework across the rest of the class.

The bottom line

On the numbers that matter most, retatrutide leads: 24.2% vs ~18.7% mean weight loss, at a nearly matched window, and with a response curve that had not plateaued. ^{[1] [2]} The difference lines up with the receptor that separates them, GIP, which retatrutide keeps and survodutide drops. But survodutide is not a weaker retatrutide; it is a different design bet, and its dedicated MASH program gives the GLP-1/glucagon combination its clearest liver-disease evidence. ^[4] The comparison is cross-trial, not head-to-head, and both compounds are still investigational. For the full retatrutide picture, see the complete retatrutide guide.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies; cross-compound comparisons are drawn from separate trials, not head-to-head studies. Retatrutide and survodutide are investigational and are not approved for human use.